<DOC>
	<DOCNO>NCT01682226</DOCNO>
	<brief_summary>The purpose study find whether addition blood stem cell close family member , add umbilical cord blood make transplant safer .</brief_summary>
	<brief_title>Myeloablative Unrelated Donor Cord Blood Transplantation With T-Cell Depleted Haplo-identical Peripheral Blood Stem Cells Patients With High Risk Hematological Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<criteria>Note : protocol eligible patient accord criterion outline divide accord age , diagnosis , performance status , organ function , prior transplantation , hematopoietic cell transplant comorbidity index ( HCTCI ) 23 , CB TNC dose standard risk ( Arm A ) high risk ( Arm B ) early posttransplant death purpose apply stop rule outcome analysis . Age : 2 70 year . Diagnosis severe aplastic anemia : eligibility discuss PI Service Chief . Such patient assess Arm B . Diagnosis high risk hematological malignancy : Any acute leukemia first complete remission ( CR ) consider high risk relapse , second third CR , relapse/refractory le equal 10 % blast bone marrow , aplasia posttherapy . This include de novo acute leukemia acute leukemia therapy relate arise antecedent hematologic disorder include myelodysplasia ( MDS ) , chronic myeloid leukemia ( CML ) myeloproliferative disorder . Juvenile myelomonocytic leukemia ( JMML ) CR , relapse le equal 10 % bone marrow blast . CML tyrosine kinase inhibitor failure chronic accelerate phase evolve acute leukemia . MDS myeloproliferative disorder lifethreatening cytopenia ( ) , and/or red blood cell platelet transfusion dependence , patient aplasia , patient excess blast less equal 10 % blast bone marrow workup . Aggressive lymphoma : patient CR1 disease high risk relapse CR23 . Indolent lymphoma chronic lymphocytic leukemia ( CLL ) : disease status provide transformed component CR . Hodgkin 's lymphoma primary refractory relapse suitable therapy PR CR small volume stable disease . Performance status : Karnofsky score ≥ 70 Lansky score ≥ 70 . • Organ function : Resting leave ventricular ejection fraction ( LVEF ) ≥ 50 % . Spirometry ( FEV1 FVC ) &amp; correct DLCO ≥ 50 % predict . In small child use history physical CT scan determine pulmonary status . Total bilirubin ≤ 1.5 mg/dl ( unless benign congenital elevate bilirubin ) ; ALT ≤ 3 x upper limit normal ( ULN ) . Calculated creatinine ( calc . creat . ) clearance ≥ 60 ml/min . Albumin ≥ 3.0 . Graft : Cryopreserved dose ≥ 1.5 x 10^7 TNC/kilogram unit double unit CB graft . This CB graft majority patient . In select patient access CB unit high TNC ( &gt; 5.0 x 10^7/kg ) , good quality CB bank single unit could consider backup CB unit standby . In select patient poor search one suitable CB unit available , unit could give single unit . This unit must TNC ≥ 2.0 x 10^7 TNC/kilogram CD34+ cell dose ≥ 1.5 x 10^5 CD34+/kilogram . Haploidentical donor 5/10 well HLAidentical use outline section 6.4 . Assignment conditioning intensity ( high dose v reduce intensity ) base patient disease status , age , extent prior therapy , organ function presence significant comorbidities outline Section 9.2 . For purpose analysis ( assignment preparative regimen ) , patient assign Arms A B summarize accord risk early posttransplant death . Eligible patient fulfill follow criterion assign risk Arm A : Age 249 year Diagnosis Any acute leukemia CR1 CR2 ( include therapyrelated arise MDS myeloproliferative disease ) . JMML CR . CML TKI failure &amp; &lt; 5 % blast . MDS &lt; 5 % blast workup . Lymphoma ( include CLL ) CR12 . Performance Status Karnofsky ≥ 80 ; Lansky ≥ 80 Organ Function Resting LVEF ≥ 60 % Spirometry ( FEV1 FVC ) &amp; correct DLCO ≥ 80 % predict . Total bilirubin normal ; ALT normal1.4 x ULN . Calc . creat . clearance ≥ 70 ml/min . Prior HSC Transplant No HCTCI score^23 02 Prethaw TNC Dose Each unit ≥ 2.0 x 10^7/kg Eligible patient meet follow criterion assign risk Arm B : Age 5070 year Diagnosis Any acute leukemia relapse/ refractory disease BM circulating blast CR3 aplasia . JMML CR . MDS aplasia ≥ 5 % blast . Lymphoma ( include CLL ) disease CR12 . Severe myelofibrosis bone marrow Performance Status Karnofsky 70 ; Lansky 70 Organ Function LVEF 5059 % . Spirometry &amp; correct DLCO 5079 % predict . Total bilirubin 1.11.5 mg/dl ; ALT 1.53 x ULN . Calc . creat . clearance 6069 ml/min . Prior HSC Transplant Yes HCTCI score23 3 high Prethaw TNC Dose Either unit 1.51.9 x 10^7/kg . Active CNS leukemia . Any acute leukemia ( include prior myelodysplasia CML blast crisis ) morphologic relapse persistent disease ≥ 10 % blast BM , double blast blood 2 week precede admission , need hydroxyurea 2 week prior admission , uncontrolled extramedullary disease . Two prior stem cell transplant kind . One prior autologous stem cell transplant within precede 12 month . One prior allogeneic stem cell transplant within precede 24 month . Prior radiation therapy 400 cGy TBI . If 200 cGy prior TBI 400 CGy TBI protocol permit . Uncontrolled viral , bacteria fungal infection time study enrollment . Seropositive NAT positive HIV . Females pregnant breast feeding . Patient guardian unable give inform consent unable comply treatment protocol include appropriate supportive care , followup , research test Cord Blood Grafts : Units select base HLAmatch patient individual cell dose unit accord current MSKCC unit selection criterion . HLAtesting do use molecular technique . The standard cord blood graft protocol consist 2 unit double unit graft although single unit permit . Each unit least 4 6 HLAA , B antigen DRB1 allele match recipient . Each unit double unit graft cryopreserved dose least 1.5 x 10^7 TNC/recipient body weight ( TNC/kg ) . In occasional patient large well matched good quality single unit rare patient one unit suitable match dose characteristic cord blood graft consist single unit describe section 6.1 . Haploidentical Donor A HLAhaploidentical related donor select available per standard MSKCC Adult BMT guideline . Mismatched family member match 5 10 HLAloci permit . Factors take account select haploidentical donor include donor age , weight , health status comorbidities , compliance , venous access , recipent donor specific HLAantibody status , NK cell alloreactivity . The donor must meet criterion outline FACTapproved SOP `` DONOR EVALUATION AND SELECTION FOR ALLOGENEIC TRANSPLANTATION '' Blood Marrow Transplant Program Manual , document E1 ( see attach , link URL : ( http : //one.mskcc.org/sites/pub/corp/bmt/Documents/D2_SOP_Donor % 20Selection % 20and % 20Evaluation_04_2015.pdf ) The donor must adequate peripheral venous catheter access leukapheresis must agree placement central catheter . The donor must &gt; 25 kg weight . Haploidentical Donor Evidence active infection ( include active urinary tract infection , upper respiratory tract infection ) evidence viral hepatitis exposure screen unless HbsAb+ HBV DNA negative . Medical physical reason make donor unlikely tolerate cooperate growth factor therapy leukapheresis . Factors place donor increase risk complication leukapheresis GCSF therapy ( e.g. , active autoimmune disease , sickle cell trait , symptomatic coronary artery disease require therapy ) . Pregnancy ( positive serum urine βHCG ) breastfeeding . Women childbearing age must avoid become pregnant study .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>CYCLOPHOSPHAMIDE ( CYTOXAN )</keyword>
	<keyword>CYCLOSPORINE</keyword>
	<keyword>FLUDARABINE</keyword>
	<keyword>G-CSF</keyword>
	<keyword>MYCOPHENOLATE MOFETIL ( MMF )</keyword>
	<keyword>Cord Blood Transplantation</keyword>
	<keyword>CliniMACS</keyword>
	<keyword>12-153</keyword>
</DOC>